PGx - CNS coverage approved

Following our announcement dated 20th June 2022, we are very happy to inform the investing public that the application of our subsidiary company, iDNA Genomics IKE, to the Greek National Health Care System (Εθνικός Οργανισμός Παροχής Υπηρεσιών Υγείας; ΕΟΠΠΥ), so that its medical genomic diagnostic test PGx-CNS be a covered product under the country’s public health care system has been approved.

This is a major milestone for the Group as this result is expected to bring an immediate increase in sales of the diagnostic test PGx-CNS, and in the long-run, it paves the way for easier admission into other national healthcare systems, especially in Europe.

The full announcement is available here.